Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12307550 | 0.85 | GCK (0.36) | GCKALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL12307529 | 0.84 | GAA (0.39) | GCKALDH1A1MEN1RAB9AKMT2A | |
| SCHEMBL12307398 | 0.83 | GCK (0.40) | GCKALDH1A1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL12307489 | 0.82 | KMT2A (0.39) | P2RX7ALDH1A1SMN1; SMN2MEN1RAB9A | |
| SCHEMBL12307527 | 0.81 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2RAB9AKMT2AMALT1 | |
| SCHEMBL12307538 | 0.80 | ADRA1A (0.35) | GCKMEN1RAB9AKMT2AATM | |
| SCHEMBL12307442 | 0.80 | GRM5 (0.39) | GCKALDH1A1SMN1; SMN2RAB9AKMT2A | |
| SCHEMBL12307509 | 0.79 | GRM5 (0.41) | GCKALDH1A1MEN1KMT2A | |
| SCHEMBL12307596 | 0.78 | MAPK13 (0.38) | GCKSMN1; SMN2MEN1RAB9AKMT2A | |
| SCHEMBL12307566 | 0.77 | GRM5 (0.35) | GCKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230472-A1 | RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R5, PIK3R4, PIK3R1 | RBP4 3916/4885P2RX7 3294/4885GCK 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.